What are the recommended diagnostic tests, treatment indications, first‑line antiviral therapy, monitoring schedule, and vaccination recommendations for a patient with chronic hepatitis B infection?

Management of Chronic Hepatitis B Infection

Initial Diagnostic Evaluation

All HBsAg-positive persons should be referred to a specialist or experienced primary care provider for comprehensive evaluation and management. 1

Essential Serologic Testing

• HBsAg and anti-HBc (total) confirm chronic infection when HBsAg persists beyond 6 months 1
• IgM anti-HBc should be negative in chronic infection (distinguishes from acute hepatitis B) 1
• HBeAg and anti-HBe status determines disease phase and treatment eligibility 1
• Anti-HBs testing identifies resolved infection or vaccine response 1
• HBV DNA quantification using real-time PCR assays is essential, reported in IU/mL 1

Coinfection Screening

• HIV, HCV, and HDV serologies must be tested in all patients at risk 1, 2
• Anti-HAV (total or IgG) to determine hepatitis A vaccination need 1

Liver Disease Assessment

• ALT, AST, bilirubin, albumin, prothrombin time/INR, and platelet count assess disease severity 1
• Baseline abdominal ultrasound for all HBsAg-positive persons ≥20 years to screen for HCC 1
• Transient elastography or serum fibrosis markers can replace liver biopsy for fibrosis assessment 1
• Liver biopsy is recommended when treatment decision is uncertain, particularly with intermittent ALT elevation, but not mandatory if cirrhosis is clinically evident 1

Critical History Elements

• Family history of HBV infection and liver cancer 1, 3
• Alcohol consumption (abstinence should be strongly recommended) 1
• Risk factors including injection drug use, sexual contacts, blood transfusions, and travel to endemic areas 3, 2

---

Treatment Indications

Treatment is indicated for patients in the immune-active phase with evidence of ongoing liver inflammation and viral replication. 1

HBeAg-Positive Chronic Hepatitis B

• ALT >2× upper limit of normal (ULN) AND HBV DNA >20,000 IU/mL for 3-6 months 2
• Any cirrhosis (compensated or decompensated) regardless of ALT or HBV DNA levels 1

HBeAg-Negative Chronic Hepatitis B

• HBV DNA ≥2,000 IU/mL AND elevated ALT 1, 2
• Any cirrhosis independent of ALT or HBV DNA levels 1

Patients NOT Indicated for Treatment

• Immune-tolerant phase (HBeAg-positive, very high HBV DNA, persistently normal ALT) 1
• Inactive carrier phase (HBeAg-negative, anti-HBe-positive, HBV DNA <2,000 IU/mL, normal ALT) 1

---

First-Line Antiviral Therapy

Nucleos(t)ide analogues with high genetic barriers to resistance (entecavir, tenofovir disoproxil, or tenofovir alafenamide) should be considered first-line treatment for chronic hepatitis B. 2, 4

Nucleos(t)ide Analogue Monotherapy

• Entecavir, tenofovir disoproxil, or tenofovir alafenamide are preferred due to significantly reduced resistance risk compared to lamivudine or adefovir 4
• Indefinite treatment duration is required for most patients, as cure rates (HBsAg loss) remain low at 1-12% 4
• Well-tolerated with minimal side effects 4
• Safe in decompensated cirrhosis (unlike peginterferon) 1

Peginterferon Alfa Alternative

• Finite duration therapy (48 weeks for HBeAg-positive, 12 months for HBeAg-negative) 1
• Immune-mediated control with possibility of sustained off-treatment response 1
• Contraindicated in decompensated cirrhosis and limited by poor tolerability, bone marrow suppression, and neuropsychiatric side effects 1, 4
• May be considered in highly selected compensated cirrhosis patients after careful risk-benefit assessment 1

Combination Therapy NOT Recommended

• Peginterferon plus nucleos(t)ide analogue combination offers no significant advantage over monotherapy as initial treatment 1

---

Monitoring Schedule

Untreated Patients Not Meeting Treatment Criteria

• ALT and HBV DNA every 3-6 months 1, 2
• HBeAg/anti-HBe every 6-12 months 1

Uncertain Treatment Indication ("Grey Area")

• ALT and HBV DNA every 1-3 months 1
• HBeAg/anti-HBe every 2-6 months 1
• Non-invasive fibrosis assessment or liver biopsy if uncertainty persists 1

Treated Patients

• HBV DNA monitoring to confirm viral suppression (primary efficacy endpoint) 2
• ALT monitoring during treatment 2
• HCC surveillance with ultrasound every 6 months in cirrhotic patients 2

---

Vaccination and Prevention Recommendations

Hepatitis A Vaccination

All anti-HAV negative patients with chronic hepatitis B should receive 2 doses of hepatitis A vaccine 6-18 months apart. 1, 2

• Coinfection with hepatitis A increases mortality risk 5.6- to 29-fold in HBV carriers 1

Contact Management and HBV Vaccination

• All sexual and household contacts should be tested for HBsAg, anti-HBc, and anti-HBs 1
• Vaccinate all contacts negative for these markers with standard 3-dose HBV vaccine series 1, 2
• Post-vaccination anti-HBs testing is recommended for newborns of HBV-infected mothers, healthcare workers, sexual partners of carriers, HIV-infected persons, dialysis patients, and immunocompromised individuals 1

Newborn Prophylaxis

Newborns of HBV-infected mothers should receive HBIG and hepatitis B vaccine at delivery, followed by completion of the 3-dose vaccine series. 1

Transmission Prevention Counseling

• Counsel patients on preventing HBV transmission to others 1, 3
• Strongly recommend alcohol abstinence or very limited consumption 1, 3
• Recommend non-smoking 1

---

Common Pitfalls and Caveats

• Do not rely on single ALT or HBV DNA measurement for treatment decisions, as levels fluctuate; monitor over 3-6 months 1
• Quantitative HBsAg testing can help differentiate immune-active from immune-tolerant or inactive phases when standard criteria are unclear 1
• Transient elastography results may be falsely elevated with severe ALT elevation; interpret cautiously with specific cut-offs 1, 5
• HCC screening should begin at age 20 years in all HBsAg-positive persons, not age 40, as younger patients can develop HCC 1
• Booster vaccination is NOT needed in immunocompetent vaccinated persons even if anti-HBs declines, but IS needed in dialysis and immunocompromised patients if anti-HBs <10 mIU/mL 1